Engineering the Human Microbiome Shows Promise for Treating Disease
By Justin L. Sonnenburg,
Scientific American
| 02. 17. 2015
Untitled Document
In the not too distant future each of us will be able to colonize our gut with genetically modified “smart” bacteria that detect and stamp out disease at the earliest possible moment. This scenario may sound like the premise for a sci-fi flick, but it is a very real possibility. Microbiome engineering holds great promise because of advances in the field of synthetic biology, which strives to create and rewire biological organisms so they perform desired tasks. Synthetic biologists are attempting to turn bacterial cells into the biological equivalent of the silicon wafer. These principles have been primarily applied to organisms for biofuel production, but the resulting techniques and genetic tool kit, when applied to our resident microbes, will have profound consequences for human health.
These resident microbes are adept at sensing what food is present, whether any pathogens are lurking and what the inflammatory state of the gut is—their survival depends on it. The model gut-resident bacterial species that we are using in our laboratory for initial tests, Bacteroides thetaiotaomicron, possesses more than 100 genetic circuits...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...